^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Thymic Carcinoma
    Drug:Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    Eisai Press Release
    Title:

    LENVIMA®(LENVATINIB) APPROVED FOR ADDITIONAL INDICATION OF UNRESECTABLE THYMIC CARCINOMA IN JAPAN

    Published date:
    03/23/2021
    Excerpt:
    Eisai Co., Ltd….and MSD K.K….announced today that LENVIMA® (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, has been approved in Japan for the additional indication of treatment of unresectable thymic carcinoma.
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    12/04/2020
    Excerpt:
    Thymomas and Thymic Carcinomas: PRICIPLES OF SYSTEMIC THERAPY...Preferred…Lenvatinib...